CareDx, Inc. (CDNA) Expected to Post Quarterly Sales of $11.96 Million
Wall Street brokerages expect that CareDx, Inc. (NASDAQ:CDNA) will post $11.96 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for CareDx’s earnings. The highest sales estimate is $12.27 million and the lowest is $11.65 million. CareDx posted sales of $12.48 million during the same quarter last year, which would suggest a negative year over year growth rate of 4.2%. The firm is expected to issue its next earnings results on Wednesday, November 8th.
According to Zacks, analysts expect that CareDx will report full year sales of $11.96 million for the current year, with estimates ranging from $46.91 million to $48.29 million. For the next fiscal year, analysts forecast that the business will post sales of $62.98 million per share, with estimates ranging from $62.17 million to $63.80 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow CareDx.
CareDx (NASDAQ:CDNA) last announced its quarterly earnings data on Thursday, August 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.19). CareDx had a negative net margin of 61.27% and a negative return on equity of 85.68%. The company had revenue of $12.05 million during the quarter, compared to analysts’ expectations of $11.87 million.
A number of equities analysts have issued reports on the stock. Zacks Investment Research cut shares of CareDx from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. ValuEngine upgraded shares of CareDx from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 24th. Piper Jaffray Companies restated an “overweight” rating and set a $7.00 target price (up previously from $3.00) on shares of CareDx in a research report on Tuesday, September 26th. Raymond James Financial, Inc. upgraded shares of CareDx from a “market perform” rating to a “buy” rating and set a $6.50 price target for the company in a report on Wednesday, September 27th. Finally, Craig Hallum reiterated a “buy” rating and set a $10.00 price target (up from $4.00) on shares of CareDx in a report on Monday, October 9th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $6.69.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/24/caredx-inc-cdna-expected-to-post-quarterly-sales-of-11-96-million.html.
Shares of CareDx (NASDAQ CDNA) opened at 5.62 on Tuesday. The company’s 50-day moving average is $4.18 and its 200 day moving average is $2.04. The stock’s market cap is $126.68 million. CareDx has a 52 week low of $0.76 and a 52 week high of $6.69.
In other news, major shareholder Neil Gagnon purchased 21,448 shares of the stock in a transaction dated Monday, August 28th. The stock was acquired at an average cost of $2.77 per share, for a total transaction of $59,410.96. Following the completion of the acquisition, the insider now directly owns 903,731 shares in the company, valued at approximately $2,503,334.87. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders have bought 75,030 shares of company stock valued at $226,758. Insiders own 5.40% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of CDNA. Royce & Associates LP grew its holdings in shares of CareDx by 39.3% during the second quarter. Royce & Associates LP now owns 733,287 shares of the company’s stock worth $814,000 after buying an additional 206,815 shares in the last quarter. Stonepine Capital Management LLC purchased a new stake in shares of CareDx during the second quarter worth about $212,000. Gagnon Securities LLC grew its holdings in shares of CareDx by 2.9% during the second quarter. Gagnon Securities LLC now owns 2,084,292 shares of the company’s stock worth $2,314,000 after buying an additional 57,954 shares in the last quarter. Finally, Trellus Management Company LLC purchased a new stake in shares of CareDx during the third quarter worth about $100,000. Institutional investors and hedge funds own 25.51% of the company’s stock.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.